The inhibition of isoforms of nitric oxide synthase: non-cardiovascular aspects

被引：1

作者：

Pitzele, BS ^{[1
]}

机构：

[1] GD Searle & Co, Skokie, IL 60077 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 1999年 / 9卷 / 05期

关键词：

amidines; amino acid; aminoguanidine; arginine; cancer; central nervous system; diabetes; eNOS; guanidines; inflammation; iNOS; nitric oxide (NO); NO inhibition; nitric oxide synthase (NOS); nNOS; NOS expression targinine; NOS gene; NOS patents; ovulation; septic shock;

D O I：

10.1517/13543776.9.5.549

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The very recent patent literature covering the inhibition of the various isoforms of nitric oxide synthase (NOS) is reviewed. Claims are generally for therapy of various inflammatory states, for therapy for a number of central nervous system (CNS) indications, and cancer therapy. Patent applications covering other aspects of control of nitric oxide (NO) concentrations in mammals are very briefly reviewed, although they fall outside of the scope of NOS per se. This includes agents that release NO in situ. Same applications covering the NOS genome are also described.

引用

页码：549 / 556

页数：8